Cardiology › Atrial Fibrillation

Benefit-Risk Analysis for Atrial Fibrillation Therapies

Atrial fibrillation management requires continuous balancing of stroke prevention against bleeding risk, with treatment decisions spanning DOACs, antiarrhythmic drugs, catheter ablation, and left atrial appendage closure. ArcaScience provides integrated BRA across pharmacological and interventional strategies using CHA₂DS₂-VASc and HAS-BLED frameworks enhanced by AI-driven patient-level risk modeling.

See Platform Request Demo

60,000,000+

People living with AFib worldwide

1,900+

AFib therapy trials analyzed

64%

Stroke risk reduction with DOACs vs. no anticoagulation

Increased stroke risk in untreated AFib

Disease Overview

Why Atrial Fibrillation Demands Specialized BRA

AFib therapy is defined by the fundamental tension between preventing thromboembolic stroke and causing hemorrhagic complications. With DOACs replacing warfarin, rhythm versus rate control strategies evolving based on EAST-AFNET 4, and catheter ablation expanding into first-line therapy, benefit-risk assessment must integrate pharmacological, interventional, and patient-specific variables simultaneously.

Stroke vs. Bleeding Risk Balancing

CHA₂DS₂-VASc scoring guides anticoagulation initiation, while HAS-BLED estimates bleeding risk, but these scores have limited discriminatory power in individual patients. DOACs (apixaban from ARISTOTLE, rivaroxaban from ROCKET AF, edoxaban from ENGAGE AF-TIMI 48) each have distinct pharmacokinetic profiles affecting efficacy and safety. BRA must model patient-level stroke-bleeding tradeoffs accounting for age, renal function, concomitant antiplatelet therapy, and fall risk.

Rhythm vs. Rate Control Strategy

EAST-AFNET 4 demonstrated that early rhythm control improves cardiovascular outcomes, shifting the paradigm from the AFFIRM-era rate control preference. However, antiarrhythmic drugs (amiodarone, flecainide, dronedarone, sotalol) carry significant proarrhythmic, thyroid, pulmonary, and hepatic toxicities. Catheter ablation (CABANA, CASTLE-AF) offers rhythm control without chronic drug exposure but introduces procedural risks including cardiac tamponade, pulmonary vein stenosis, and esophageal injury.

Anticoagulation in Special Populations

DOAC dosing in renal impairment (CrCl 15-50 mL/min) requires careful dose reduction with differing thresholds per agent. Frail and elderly patients face amplified bleeding risk but also the highest stroke risk, creating a narrow therapeutic window. Perioperative anticoagulation management, bridging decisions, and anticoagulation around catheter ablation or left atrial appendage closure (WATCHMAN device) demand procedure-specific BRA that accounts for temporary interruption risks.

Platform Capabilities

How ArcaScience Addresses AFib BRA

Our modules are configured with AFib anticoagulation and rhythm control data, stroke-bleeding prediction models trained on DOAC trial populations, and regulatory templates for anticoagulant and antiarrhythmic submissions.

Data Intelligence

AFib Anticoagulation & Rhythm Data

1,900+ AFib trials including ARISTOTLE, ROCKET AF, ENGAGE AF-TIMI 48, RE-LY, CABANA, CASTLE-AF, and EAST-AFNET 4 datasets. Comprehensive bleeding and stroke event databases covering DOACs, warfarin, antiarrhythmic drugs, and catheter ablation outcomes with real-world data from anticoagulation clinics and nationwide AFib registries spanning 2M+ patient-years.

Explore Data Engine →

Decision Intelligence

Stroke-Bleeding AI Models

AI models for patient-level stroke-bleeding tradeoff optimization beyond CHA₂DS₂-VASc and HAS-BLED, renal function-adjusted DOAC dosing simulation, comparative DOAC efficacy-safety profiling (apixaban vs. rivaroxaban vs. edoxaban), catheter ablation complication risk prediction, and antiarrhythmic drug proarrhythmia detection using ECG and electrophysiology data patterns.

Explore AI Models →

Automated Outputs

Anticoagulant Regulatory Outputs

PSURs with detailed bleeding event analysis by type (major, CRNM, minor) and location (intracranial, GI, genitourinary), RMPs with renal dose adjustment protocols and perioperative management guidance, comparative effectiveness documents for DOAC class differentiation, and post-marketing commitment reports for stroke prevention efficacy in real-world populations aligned with FDA and EMA anticoagulant guidance.

Explore Outputs →

AFib Intelligence

Platform Performance in Atrial Fibrillation

4,200,000,000+

AFib anticoagulation data points tracked

68%

Faster bleeding signal detection

Stroke-bleeding prediction models deployed

AFib regulatory submissions supported

Case Evidence — Atrial Fibrillation

DOAC Comparative Safety Analysis for Renal Impairment Populations

Challenge

A DOAC manufacturer needed to demonstrate their agent's favorable benefit-risk profile in patients with moderate renal impairment (CrCl 25-50 mL/min), where reduced-dose regimens apply but real-world dosing errors are common. The regulatory authority required evidence that dose-reduced patients maintained stroke protection without excess bleeding compared to competitors.

Result

ArcaScience integrated ARISTOTLE, ROCKET AF, and ENGAGE AF-TIMI 48 subgroup analyses with real-world renal impairment cohort data from 180,000+ patients. The platform identified that inappropriate dose reduction (occurring in 15-30% of patients) significantly increased stroke risk, enabling the company to propose enhanced renal monitoring guidance that was adopted into the updated product label.

2.8x

Faster renal safety subgroup analysis

38%

Reduction in inappropriate dosing signal noise

View All Case Studies →

The renal impairment BRA was the linchpin of our label update submission. ArcaScience helped us disentangle appropriate dose reduction from inappropriate underdosing in real-world data, which was exactly the differentiation regulators needed to see. The platform turned what would have been a six-month manual analysis into a three-week deliverable.

Director of Cardiovascular Pharmacovigilance

Global Anticoagulant Manufacturer

Frequently Asked Questions

Atrial Fibrillation BRA

Our platform provides head-to-head comparative BRA between apixaban, rivaroxaban, edoxaban, and dabigatran using data from ARISTOTLE, ROCKET AF, ENGAGE AF-TIMI 48, and RE-LY alongside real-world registries. AI models analyze net clinical benefit (stroke prevention minus major bleeding) across patient subgroups defined by age, renal function, body weight, and concomitant medications. This supports formulary decisions, treatment guidelines, and regulatory differentiation claims.

Yes. Using data from CABANA, CASTLE-AF, and EAST-AFNET 4, our platform models the benefit-risk of catheter ablation versus antiarrhythmic drug therapy for rhythm control. The analysis incorporates procedural complication rates (cardiac tamponade at 1-2%, pulmonary vein stenosis, phrenic nerve injury, atrioesophageal fistula), recurrence rates requiring repeat ablation, and the long-term avoidance of antiarrhythmic drug toxicities. For heart failure patients with AFib, CASTLE-AF data demonstrates mortality benefit from ablation that reframes the benefit-risk calculus.

Each DOAC has distinct renal dose adjustment thresholds: apixaban uses serum creatinine plus age and weight criteria, rivaroxaban and edoxaban use CrCl cutoffs, and dabigatran has the most renal-dependent clearance. Our models simulate dose-exposure-response relationships across the renal function spectrum, identify patients at risk of inappropriate dosing (both under- and over-dosing), and flag real-world dosing patterns that deviate from label recommendations. This supports pharmacovigilance for dose-related adverse events and label optimization.

Yes. Perioperative DOAC management is a major source of adverse events, with decisions around timing of interruption, bridging anticoagulation, and resumption carrying significant stroke and bleeding risks. Our platform models procedure-specific bleeding risk (high vs. low), DOAC half-life considerations based on renal function, and the evidence against routine heparin bridging from the BRIDGE trial. This supports risk minimization measures in product labels and perioperative management guidelines included in regulatory submissions.

See ArcaScience Applied to Atrial Fibrillation

Request a demonstration focused on AFib BRA. Our cardiovascular scientists will present DOAC comparative safety analysis, stroke-bleeding tradeoff models, catheter ablation benefit-risk evaluation, and renal impairment dosing frameworks.

Request AFib Briefing Explore the Platform →